)
Edge11 Sep 2026
Texas Pacific Land Corporation: Keeper of the Permian Basin
Land once granted to a failed 19th-century railroad now generates royalties for Texas Pacific Land Corporation across the Permian Basin.
CG Oncology
CG Oncology (CGON) investor relations material
CG Oncology Investor presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Investor presentation summary25 Sep, 2026
Mechanism of action and clinical rationale
Selectively replicates in and lyses bladder cancer cells, triggering a chain reaction of tumor cell death.
Amplifies anti-tumor immune response by activating T and B cells, inducing immunologic memory.
Clinical development and trial design
Programs target high-risk and intermediate-risk NMIBC, including BCG-naïve, BCG-exposed, and BCG-unresponsive populations.
Multiple phase 2/3 studies and expanded access programs address significant unmet needs in NMIBC.
Efficacy and safety outcomes
Monotherapy in BOND-003 Cohort C achieved a 75.5% complete response rate, with 97.3% free from progression to MIBC at 24 months.
Combination therapy in CORE-008 Cohort CX showed CR rates of 85.7% (ITT) and 92.3% (efficacy-evaluable), with no treatment-related progression or severe adverse events.
No grade 3 or higher treatment-related adverse events, deaths, or discontinuations reported in key cohorts.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from CG Oncology
- Durable efficacy, operational simplicity, and pivotal trial catalysts drive strong outlook.CGON
Morgan Stanley 24th Annual Global Healthcare Conference - Late-stage trials and regulatory progress position cretostimogene for near-term market entry.CGON12th Annual Cantor Fitzgerald Global Healthcare Conference
- Net loss increased on higher R&D and G&A costs, with strong cash reserves and major clinical progress.CGONQ2 2026
- Cretostimogene shows high response rates and safety, with pivotal data and commercial advances ahead.CGONMorgan Stanley 22nd Annual Global Healthcare Conference
- Pivotal trials for NMIBC therapy show strong efficacy, with key data readouts expected soon.CGON44th Annual J.P. Morgan Healthcare Conference
- Cretostimogene delivers leading efficacy and safety in NMIBC, targeting a large market opportunity.CGONInvestor presentation
- High efficacy and safety of cretostimogene enabled bladder preservation in most NMIBC patients.CGONConference presentation
- Pivotal NMIBC trial results and regulatory filings position cretostimogene for first approval.CGONGoldman Sachs 47th Annual Global Healthcare Conference 2026
- Cretostimogene shows 75% CR rate and strong safety in NMIBC, with pivotal data and 2026 launch expected.CGONTD Cowen 45th Annual Healthcare Conference
Next CG Oncology earnings date
Q3 202612 Nov, 2026
CG Oncology
Next CG Oncology earnings date
Q3 202612 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage